Study the glossary step by step
Pick a category, work through Foundations first, then Intermediate and Advanced. Foundations are the terms other pages refer to most. Use "Save my progress" on a term page and it is ticked here.
Regulatory
0 / 101 studiedFDA, EU MDR/IVDR, and global pathways for getting devices to market.
Step 1: Foundations (34)
- EU In Vitro Diagnostic Regulation (IVDR)
- 510(k) Premarket Notification (510(k))
- EU Medical Device Regulation (MDR)
- Premarket Approval (PMA)
- Notified Body (NB)
- De Novo Classification Request (De Novo)
- EUDAMED
- High-Risk AI System (EU AI Act)
- Unique Device Identification (UDI)
- IVDR Risk Classes A–D
- Labeling
- IMDRF
- IVDR Performance Evaluation
- Combination Product
- Substantial Equivalence (SE)
- Authorized Representative (EU) (EC REP)
- CE Mark
- Clinical Performance (IVDR)
- General Safety and Performance Requirements (GSPRs)
- Instructions for Use (IFU)
- Predicate Device
- Abbreviated 510(k)
- Benefit-Risk Determination
- Breakthrough Device Designation (BDD)
- FDA Recognized Consensus Standards
- Refuse to Accept (RTA)
- Analytical Performance (IVDR)
- Class III Device
- Common Specifications (CS)
- Common Specifications (IVDR) (CS)
- General Controls
- Intended Use
- Letter to File (LTF)
- Medical Device Coordination Group Guidance (MDCG)
Step 2: Intermediate (34)
- Metrological Traceability (IVDR)
- MHRA / UKCA Marking (MHRA / UKCA)
- Modular PMA
- PMA Supplement Types
- Q-Submission (Pre-Submission) (Q-Sub / Pre-Sub)
- Real-Time PMA Supplement Review
- Request for Designation (RFD)
- Scientific Validity (IVDR)
- Special 510(k) (Special 510(k))
- Special Controls
- Accreditation Scheme for Conformity Assessment (ASCA)
- AI Act Conformity Assessment (Medical Devices)
- AI Act Technical Documentation (Annex IV)
- Clinical Evaluation Consultation Procedure (CECP)
- Companion Diagnostic (IVDR) (CDx)
- eSTAR
- EU Reference Laboratory (EURL) (EURL)
- Fundamental Rights Impact Assessment (FRIA)
- General-Purpose AI Model (GPAI)
- Indications for Use (IFU (statement))
- IVDR Legacy Device
- MDR Article 117
- National Medical Products Administration (NMPA)
- Notified Body Scrutiny (IVDR Class D)
- Person Responsible for Regulatory Compliance (PRRC)
- Pharmaceuticals and Medical Devices Agency (PMDA)
- Post-Market Performance Follow-Up (IVDR) (PMPF)
- Post-Market Surveillance Plan (IVDR)
- Provider and Deployer (EU AI Act)
- Self-Test and Near-Patient Testing (IVDR)
- Summary of Safety and Clinical Performance (SSCP)
- Technical Documentation
- Therapeutic Goods Administration (TGA)
- Third-Party Review of 510(k) (3P 510(k))
Step 3: Advanced (33)
- UK Responsible Person (UKRP)
- 510(k) Summary vs 510(k) Statement
- 513(g) Request for Information (513(g))
- Additional Condition for Nonprescription Use (ACNU)
- AI Act Post-Market Monitoring
- AI Act Prohibited Practices
- AI Act Serious Incident Reporting
- AI Act Transparency Obligations
- ANVISA (ANVISA)
- Class D Batch Verification (IVDR)
- Device Master File (MAF)
- Device Reclassification Petition
- Electronic Instructions for Use (eIFU)
- Emergency Use Authorization (EUA)
- General Safety and Performance Requirements (IVDR) (GSPR)
- Genetic Testing Requirements (IVDR Article 4)
- Health Canada Medical Device Licence (MDL)
- Humanitarian Device Exemption (HDE)
- Importer and Distributor Obligations (EU)
- In-House IVDs (Article 5(5))
- ISO 20916
- IVDR Conformity Assessment Routes
- IVDR Transitional Provisions
- Medical Device User Fee Amendments (MDUFA)
- Ministry of Food and Drug Safety (Korea) (MFDS)
- NMPA Innovative Medical Device Pathway
- Performance Study Application (IVDR)
- Safer Technologies Program (STeP)
- Saudi Food and Drug Authority (SFDA)
- Summary of Safety and Performance (IVDR) (SSP)
- Swissmedic
- Systemic Risk (GPAI)
- WHO Prequalification (Diagnostics) (WHO PQ Dx)
Quality & Risk
0 / 39 studiedQMS, risk management, and process controls for medical devices.
Step 1: Foundations (13)
- Quality System Regulation (QSR / 21 CFR 820)
- Design Controls
- Corrective and Preventive Action (CAPA)
- Medical Device Single Audit Program (MDSAP)
- Quality Management System Regulation (QMSR)
- Risk Management File (RMF)
- Design History File (DHF)
- Risk Management
- Complaint Handling
- Failure Mode and Effects Analysis (FMEA)
- Management Review
- Change Control
- Fault Tree Analysis (FTA)
Step 2: Intermediate (13)
Step 3: Advanced (13)
- CAPA Effectiveness Check
- Document Control
- ISO 31000
- Management Representative
- Post-Production Information (Risk)
- Process FMEA vs Design FMEA (PFMEA / DFMEA)
- Production and Process Controls
- Quality Manual
- Risk Acceptability Matrix
- Servicing (21 CFR 820.200)
- Summative vs. Formative Evaluation
- Training Records
- Use Specification
Cybersecurity
0 / 61 studiedThreat modeling, SBOMs, and secure-by-design for connected devices.
Step 1: Foundations (21)
- Premarket Cybersecurity Submission
- Section 524B of the FD&C Act (524B)
- Threat Modeling
- Secure Product Development Framework (SPDF)
- IEC 81001-5-1
- Software Bill of Materials (SBOM)
- HIPAA (HIPAA)
- NIST Cybersecurity Framework (NIST CSF)
- Postmarket Cybersecurity Management
- Vulnerability Exploitability eXchange (VEX)
- Coordinated Vulnerability Disclosure (CVD)
- Secure Boot
- AAMI TIR57
- HSCC Joint Security Plan (HSCC JSP)
- Common Vulnerabilities and Exposures (CVE)
- ISO/IEC 27001 (ISO 27001)
- Patchability
- Common Vulnerability Scoring System (CVSS)
- CycloneDX
- IEC 80001-1
- Penetration Testing
Step 2: Intermediate (20)
- Hardcoded Credentials
- Health Industry Cybersecurity Practices (HICP)
- Health Information Sharing and Analysis Center (H-ISAC)
- HITECH Act (HITECH)
- IMDRF Principles and Practices for Medical Device Cybersecurity
- NIST SP 800-53 / 800-171 (NIST 800-53/171)
- Over-the-Air Updates (OTA)
- PHI and ePHI
- SPDX (SPDX)
- De-Identification of Health Data
- Legacy Device Cybersecurity
- SAST and DAST
- STRIDE Threat Model (STRIDE)
- AAMI SW96
- Brainjacking
- CISA Known Exploited Vulnerabilities Catalog (KEV)
- FedRAMP (FedRAMP)
- Healthcare and Public Health Cybersecurity Performance Goals (HPH-CPG)
- HITRUST CSF (HITRUST)
- ICS Medical Advisory (ICSMA)
Step 3: Advanced (20)
- Manufacturer Disclosure Statement for Medical Device Security (MDS2)
- Medjacking
- SOC 2
- Code Signing
- Cryptographic Agility
- Hardware Root of Trust (HRoT)
- Medhacking
- MITRE ATT&CK (ATT&CK)
- MITRE D3FEND (D3FEND)
- OWASP IoT and Embedded Application Security
- Refuse to Accept (Cybersecurity) (RTA (cyber))
- Secure Software Development Framework (SSDF)
- Supply-chain Levels for Software Artifacts (SLSA)
- AAMI TIR97 (TIR97)
- Common Weakness Enumeration (CWE)
- LINDDUN
- NIST CSWP 35, Cybersecurity Threat Modeling the Genomic Data Sequencing Workflow (NIST CSWP 35)
- Side-Channel Attack
- Software Safety Case
- Zero Trust Architecture (ZTA)
Clinical & Trials
0 / 52 studiedClinical evidence, investigations, and human-factors studies.
Step 1: Foundations (18)
- Investigational Device Exemption (IDE)
- ICH E6 Good Clinical Practice (GCP)
- Pivotal Trial
- Real-World Evidence (RWE)
- Human Factors Engineering (HFE)
- Adaptive Trial Design
- Informed Consent
- Institutional Review Board (IRB)
- ALCOA+
- Composite Endpoint
- Bayesian Trial Design
- Clinical Evaluation Report (CER)
- Decentralized Clinical Trial (DCT)
- Early Feasibility Study (EFS)
- Electronic Data Capture (EDC)
- IDE Supplement
- Protocol Deviation
- Source Data Verification (SDV)
Step 2: Intermediate (17)
- Trial Master File (TMF)
- Adverse Event (AE)
- Case Report Form (CRF)
- Clinical Investigation Plan (CIP)
- Data Safety Monitoring Board (DSMB)
- Feasibility Study
- Investigator Brochure (IB)
- Minimal Clinically Important Difference (MCID)
- Primary and Secondary Endpoints
- Risk-Based Monitoring (RBM)
- Surrogate Endpoint
- Unanticipated Adverse Device Effect (UADE)
- Use Error
- Analytical Sensitivity
- Blinding and Masking
- Clinical Evaluation Plan (CEP)
- Core Laboratory
Step 3: Advanced (17)
- First-in-Human Study (FIH)
- IDE Annual Progress Report
- Intent-to-Treat vs Per-Protocol (ITT / PP)
- Limit of Detection / Limit of Quantitation (LoD / LoQ)
- Lost to Follow-up
- Non-Inferiority Trial
- Performance Study (IVDR)
- Pharmacogenomics (PGx)
- Real-World Data (RWD)
- Sample Size and Statistical Power
- Serious Adverse Event (SAE)
- Sham Control
- Electronic Patient-Reported Outcome (ePRO)
- Investigator-Initiated Trial (IIT)
- Master Protocol (Basket / Umbrella / Platform)
- Pragmatic Trial
- Propensity Score Methods
Standards
0 / 25 studiedISO, IEC, AAMI, and other consensus standards used by regulators.
Step 1: Foundations (9)
Step 2: Intermediate (8)
Software & AI
0 / 31 studiedSaMD, SiMD, AI/ML models, and software lifecycle terminology.
Step 1: Foundations (11)
Step 2: Intermediate (10)
Step 3: Advanced (10)
Manufacturing
0 / 22 studiedDesign transfer, production controls, and supply chain terms.
Step 1: Foundations (8)
Step 2: Intermediate (7)
Post-Market
0 / 22 studiedSurveillance, vigilance, recalls, and lifecycle management.
Step 1: Foundations (8)
Step 2: Intermediate (7)
Investment & Finance
0 / 47 studiedVenture financing, term sheets, valuation, and capital structure for MedTech startups.
Step 1: Foundations (16)
Step 2: Intermediate (16)
- Liquidity Event
- Milestone Payment
- Milestone-Based Tranche
- Non-Dilutive Funding
- Post-Money Valuation
- Protective Provisions
- Simple Agreement for Future Equity (SAFE)
- Tranched Financing
- Anti-Dilution Protection
- Board of Directors
- Common Stock
- Distribution Waterfall
- Series A / B / C Financing Rounds
- Valuation Cap
- Venture Debt
- 409A Valuation
Step 3: Advanced (15)
- Bridge Round
- Burn Rate
- Earn-Out
- Fully Diluted Shares
- Lock-Up Period
- Pay-to-Play Provision
- Priced Round
- Pro-Rata Rights
- SBIR / STTR Grants (SBIR/STTR)
- Super Pro Rata Rights
- Burn Rate and Runway
- Drag-Along and Tag-Along Rights
- Limited Partner / General Partner (LP / GP)
- Royalty Financing
- Special Purpose Acquisition Company (SPAC)
Market Segments
0 / 38 studiedTherapeutic and technology segments - cardiovascular, IVD, surgical robotics, DTx, and more.
Step 1: Foundations (13)
- In Vitro Diagnostics (IVD)
- Laboratory-Developed Test (LDT)
- Companion Diagnostic (CDx)
- Molecular Diagnostics
- Wearable Medical Devices
- Neuromodulation
- Surgical Robotics
- Wearables and Remote Patient Monitoring (RPM)
- Cardiovascular Devices
- Clinical Laboratory Improvement Amendments (CLIA)
- Digital Therapeutics (DTx)
- Orthopedic Devices
- Point-of-Care Diagnostics (POC)
Step 2: Intermediate (13)
Reimbursement
0 / 37 studiedCoding, coverage, and payment pathways across CMS, commercial payers, and global HTAs.
Step 1: Foundations (13)
- New Technology Add-On Payment (NTAP)
- ASC Site-of-Service Shift
- National and Local Coverage Determinations (NCD / LCD)
- RWE for Reimbursement
- CPT Codes (CPT)
- Current Procedural Terminology Codes (CPT)
- LCD and NCD
- HCPCS Codes (HCPCS)
- Health Technology Assessment (HTA)
- Outpatient Prospective Payment System (OPPS)
- Quality-Adjusted Life Year (QALY)
- Transitional Pass-Through Payment (TPT)
- Value-Based Care (VBC)
Step 2: Intermediate (12)
- Coverage with Evidence Development (CED)
- Incremental Cost-Effectiveness Ratio (ICER)
- Inpatient Prospective Payment System (IPPS)
- MS-DRG (MS-DRG)
- Transitional Coverage for Emerging Technologies (TCET)
- Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)
- Medicare Administrative Contractor (MAC)
- MolDx Program
- Protecting Access to Medicare Act (PAMA)
- Budget Impact Model (BIM)
- Bundled Payment
- Category III CPT Code
Step 3: Advanced (12)
- Category III CPT Codes
- Health Economics and Outcomes Research (HEOR)
- ICD-10-CM / ICD-10-PCS
- Joint Clinical Assessment (JCA)
- Medicare Physician Fee Schedule (MPFS)
- 340B Drug Pricing Program (340B)
- Ambulatory Payment Classification (APC)
- CMS IDE Coverage (Category A & B)
- Prior Authorization
- Proprietary Laboratory Analyses Codes (PLA)
- Recovery Audit Contractor (RAC)
- Site-Neutral Payment
Commercialization
0 / 23 studiedGo-to-market, sales channels, KOLs, and hospital purchasing dynamics.
Step 1: Foundations (8)
Step 2: Intermediate (8)
Industry Bodies
0 / 15 studiedVendor-neutral trade associations, standards-setting organizations, professional societies, public-private consortia, and non-commercial accelerator programs.